FY2025 Earnings Forecast for LRMR Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2025 earnings per share (EPS) estimate for Larimar Therapeutics down to ($1.80), compared to a previous estimate of ($1.79), indicating a bearish outlook.
• The current consensus estimate for Larimar's full-year earnings is ($1.15) per share, highlighting a significant disparity between analyst expectations and the revised forecasts.
• Company insider James E. Flynn purchased 9,375,000 shares at $3.20 each, increasing his holdings substantially and showing confidence in the company's future despite the bearish analyst sentiment.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Larimar Therapeutics in a research note issued on Wednesday, September 3rd. Leerink Partnrs analyst J. Park now forecasts that the company will post earnings of ($1.80) per share for the year, down from their previous forecast of ($1.79). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics' FY2027 earnings at ($1.96) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.18) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.06.

LRMR has been the topic of several other research reports. JMP Securities dropped their target price on shares of Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating on the stock in a research report on Friday, August 15th. Guggenheim reissued a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. Citigroup reaffirmed a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Finally, Wedbush dropped their price objective on shares of Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, June 24th. Nine analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $18.43.

Larimar Therapeutics Stock Down 5.8%

Shares of NASDAQ LRMR traded down $0.24 during trading hours on Monday, hitting $3.93. 1,334,825 shares of the stock were exchanged, compared to its average volume of 1,268,811. The company has a market cap of $325.33 million, a PE ratio of -2.52 and a beta of 0.91. The firm has a fifty day moving average price of $3.67 and a 200-day moving average price of $2.84. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $9.50.

Hedge Funds Weigh In On Larimar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. lifted its stake in shares of Larimar Therapeutics by 114.7% in the second quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company's stock worth $11,878,000 after buying an additional 2,195,923 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Larimar Therapeutics by 15.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company's stock worth $24,936,000 after buying an additional 876,431 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in shares of Larimar Therapeutics by 46.6% in the first quarter. Alyeska Investment Group L.P. now owns 1,442,473 shares of the company's stock worth $3,101,000 after buying an additional 458,396 shares in the last quarter. Cerity Partners LLC purchased a new position in shares of Larimar Therapeutics in the second quarter worth about $636,000. Finally, Nuveen LLC purchased a new position in shares of Larimar Therapeutics in the first quarter worth about $376,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director James E. Flynn bought 9,375,000 shares of the firm's stock in a transaction that occurred on Thursday, July 31st. The stock was purchased at an average cost of $3.20 per share, for a total transaction of $30,000,000.00. Following the purchase, the director directly owned 9,538,945 shares in the company, valued at approximately $30,524,624. This trade represents a 5,718.38% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.50% of the stock is currently owned by corporate insiders.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.